[An interleukin-1 beta efficacy study in the treatment of combined radiation-thermal lesions].
The experiments were carried out on F1 (CBA x C57B16) male-mice. It was shown that, in contrast to a therapeutic effect of IL-1 for the solely irradiated mice, a single subcutaneous injection of 100 micrograms/kg recombinant human IL-1 beta in 4 h after a combined radiation-thermal injury (CRTI) increased significantly the death rate of the animals within the first 2-4 days. Administration of 150 ng IL-1 per mouse in 4, 24, or 48 h after the CRTI decreased an average life-span of mice. A single injection of cytokine in 5 days after the CRTI increased the survival rate by 45%. Repeated injections IL-1 with a dose of 100 pg per mouse in 2, 4, and 6 days after the CRTI did not aid in the haematological indices and did not affect the survival rate of the animals.
Ul'ianova
L P
LP
Ketlinskiĭ
S A
SA
Budagov
R S
RS
D000208:Acute Disease; D000818:Animals; D002056:Burns / Q000188:drug therapy* / Q000401:mortality; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007375:Interleukin-1 / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D011833:Radiation Injuries, Experimental / Q000188:drug therapy* / Q000401:mortality; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors; D014916:Whole-Body Irradiation / Q000009:adverse effects
D007375:Interleukin-1; D011994:Recombinant Proteins